|
No
|
IBD
|
Sex
|
Age of anti-TNF (years)
|
Age of TB (years)
|
Interval to TB diagnosis (months)
|
Anti-TNF agents
|
TST
|
IGRA
|
Previous TB treatment
|
LTBI
|
TB prophylaxis
|
Smoking
|
TB site
|
|---|
|
1
|
UC
|
M
|
67
|
68
|
2
|
IFX
|
ND
|
(−)
|
No
|
(−)
|
ND
|
Ex
|
Lung
|
|
2
|
UC
|
M
|
66
|
67
|
10
|
IFX
|
(−)
|
(−)
|
No
|
(−)
|
ND
|
Ex
|
Lung + peritoneum
|
|
3
|
UC
|
F
|
42
|
47
|
55
|
IFX
|
(−)
|
(−)
|
No
|
(−)
|
ND
|
(−)
|
Lung
|
|
4
|
UC
|
M
|
53
|
53
|
2
|
IFX
|
ND
|
(−)
|
No
|
(−)
|
ND
|
Ex
|
Lung
|
|
5
|
UC
|
M
|
46
|
47
|
14
|
IFX > ADA
|
ND
|
(+)
|
No
|
(+)
|
INH + RFP
|
Ex
|
Lung + pleura
|
|
6
|
UC
|
M
|
60
|
60
|
4
|
IFX
|
(−)
|
(−)
|
No
|
(−)
|
ND
|
(+)
|
pleura + pericardium
|
|
7
|
CD
|
F
|
33
|
33
|
3
|
IFX
|
(−)
|
(−)
|
No
|
(−)
|
ND
|
Ex
|
Lung
|
|
8
|
CD
|
M
|
59
|
59
|
3
|
IFX
|
(−)
|
(−)
|
No
|
(−)
|
ND
|
Ex
|
Lung
|
|
9
|
CD
|
M
|
26
|
29
|
34
|
ADA
|
(−)
|
(+)
|
No
|
(+)
|
INH + RFP
|
(−)
|
Lung
|
|
10
|
CD
|
F
|
26
|
30
|
50
|
IFX > ADA
|
(−)
|
(−)
|
No
|
(−)
|
ND
|
(−)
|
Lung
|
|
11
|
CD
|
M
|
23
|
25
|
27
|
IFX
|
ND
|
(−)
|
No
|
(−)
|
ND
|
(−)
|
Lung + LN
|
|
12
|
CD
|
F
|
32
|
32
|
4
|
IFX
|
ND
|
ND
|
No
|
Unknown
|
ND
|
(−)
|
Spleen + LN
|
|
13
|
CD
|
F
|
22
|
25
|
42
|
IFX
|
(−)
|
(+)
|
No
|
(+)
|
RFP
|
(−)
|
Lung
|
|
14a
|
CD
|
F
|
37
|
42
|
67
|
IFX
|
(−)
|
(−)
|
No
|
(−)
|
ND
|
(+)
|
Lung + pleura
|
|
15
|
CD
|
M
|
24
|
32
|
95
|
IFX
|
(−)
|
(−)
|
ITBb
|
(−)
|
ND
|
(+)
|
Lung + pleura
|
|
16
|
CD
|
M
|
29
|
30
|
5
|
IFX
|
(−)
|
Indeterminate
|
No
|
(−)
|
ND
|
(−)
|
Lung
|
|
17
|
CD
|
F
|
44
|
45
|
14
|
IFX
|
(−)
|
(−)
|
No
|
(−)
|
ND
|
(−)
|
Lung
|
|
18
|
CD
|
M
|
41
|
43
|
17
|
IFX
|
(−)
|
(−)
|
Lung
|
(−)
|
ND
|
(−)
|
Lung
|
|
19
|
CD
|
F
|
41
|
43
|
24
|
IFX > ADA
|
(−)
|
(−)
|
ITBb
|
(−)
|
ND
|
(−)
|
pleura
|
|
20
|
CD
|
F
|
35
|
36
|
11
|
IFX
|
(−)
|
(−)
|
ITBb
|
(−)
|
ND
|
(−)
|
Lung + endobronchus
|
|
21
|
CD
|
M
|
25
|
26
|
1
|
IFX
|
ND
|
(−)
|
No
|
(−)
|
ND
|
(+)
|
Lung
|
- TNF, tumor necrosis factor; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; LTBI, latent tuberculosis infection; TB, tuberculosis; TST, tuberculin skin test; IGRA, interferon gamma release assay; IFX, infliximab; ADA, adalimumab; ND, not done; ITB, intestinal tuberculosis; INH, isoniazid; RFP, rifampin; Ex, ex-smoker; LN, lymph node
- aThis patent was undergoing treatment for tuberculosis at the end of the study. All other patients were completely cured after tuberculosis treatment
- bThese patients with Crohn's disease had a history of medication for tuberculosis to identify intestinal tuberculosis
